

October 11, 2019

Listing Department  
**BSE LIMITED**

P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department

**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated October 11, 2019 titled "Cadila Healthcare's API manufacturing facility at Dabhaha successfully completes USFDA inspection."

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

  
**DHAVAL N. SONI**  
**COMPANY SECRETARY**



## **Cadila Healthcare's API manufacturing facility at Dabhasa successfully completes USFDA inspection**

*Ahmedabad, 11 October 2019*

Cadila Healthcare Limited announced today that the USFDA inspected its Active Pharmaceutical Ingredients (API) manufacturing facility at Dabhasa, the group's largest API manufacturing site, from 7<sup>th</sup> to 11<sup>th</sup> October 2019. This was a cGMP audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) is issued.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 24000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*